

Summer 2025 Symposium
“Antibody Drug Conjugates: Selection, Sequencing and
Future Strategies in Solid Tumors”
Thursday, July 24, 2025
Washington, DC

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “**ineligible company**” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

| NAME | Individual's Role(s) in Activity | Nothing To Disclose | Name of Ineligible Company(s) | Nature of Relevant Financial Relationship(s) |
|-----------------------------|----------------------------------|---------------------|---|--|
| Planning Disclosures | | | | |
| Moore, Kathleen, MD | Planner/ Moderator | | Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE | Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) |

FACULTY DISCLOSURE INFORMATION

| | | | | |
|----------------------------|-------------------------------|--|--|--|
| | | | | Travel, Accommodations, Expenses (BioNTech SE) |
| Tarantino, Paolo, MD | Planner/ Moderator | | AstraZeneca, Daiichi Sankyo, Novartis, Menarini/Stemline, Gilead, Eli Lilly | Consultant (AstraZeneca; Daiichi Sankyo; Gilead; Eli Lilly) Advisor (AstraZeneca; Daiichi Sankyo; Novartis; Menarini/Stemline) Speaker (AstraZeneca; Daiichi Sankyo) |
| Speaker Disclosures | | | | |
| Cecchini, Michael, MD | Speaker | | AbbVie; Beigene; Incendia Therapeutics; Taiho; Arcus; Ipsen; BeOne Oncology; BioAlta; Medilink; Genentech, Astellas; Parbilis Medicines; 858 Therapeutics; Janssen; Eli Lilly | Honoraria/Advisory Role (AbbVie; Beigene; Incendia Therapeutics; Taiho; Arcus) Travel (Ipsen) Research Funding paid to Institution (AbbVie; Arcus; BeOne Oncology; BioAlta; Medilink; Genentech, Astellas; Parabalis Medicines; Ipsen; 858 Therapeutics; Janssen; Eli Lilly) |
| Ellisen, Leif W., MD, PhD | Speaker | | Gilead; Astra-Zeneca; Atavistik; Kisoji | Consultant |
| Gupta, Shilpa, MD | Speaker | | Bristol Meyers Squibb; Merck; J&J; AstraZeneca; BionTech; Nektar Therapeutics; UpToDate; BMS; Pfizer; Roche; Tyra Biosciences; Flare Therapeutics; Convergent Therapeutics; Novartis | Advisory Role (Bristol Meyers Squibb; Merck; J&J; AstraZeneca) Honoraria (Merck) Speaker's Bureau (Bristol Meyers Squibb) Stock (BionTech; Nektar Therapeutics) Intellectual Property, Patents, Proprietary Interests (UpToDate) Research Funding Site PI (Merck; BMS; Pfizer; Roche; Tyra Biosciences; Flare Therapeutics; Convergent Therapeutics; Novartis) |
| Krop, Ian, MD | Moderator/ Speaker | | EMD Serono; AstraZeneca; Daiichi Sankyo; Puretech; Johns Hopkins | Honoraria (EMD Serono; AstraZeneca; Daiichi Sankyo) Employment of Immediate Family Member-has Ended (Puretech) Intellectual Property, Patents, Proprietary Interests (Johns Hopkins) |
| Liu, Joyce, MD | Moderator | | AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Dicephera Pharmaceuticals; Bristol-Meyers Squibb | Advisory Board ad hoc. (AstraZeneca; Daiichi Sankyo; Eisai; Genentech) Scientific Ad Board (Dicephera Pharmaceuticals) Consulting (Bristol-Meyers Squibb) |
| LoRusso, Patricia, DO, PhD | Speaker | | Takeda; Agenesis; Pfizer; Glaxo-Smith Kline; Kyowa Kirin Pharmaceutical Development; Kineta; I-Mab; Mekanistic; Acuate Therapeutics; Atreca Development; Schrodinger; Prelude; Wells Therapeutics; Kivu; Compass Tx; Zai Lab; Abdera; AstraZeneca; EMD Serono; Quanta Therapeutics; Cullinan; Boehringer Ingelheim; SOTIO; (Amgen CodeBreak 202; DrenBio; National Cancer Institute/NIH/DDHS; AstraZeneca Pharmaceutical LP; Merck; NIH/NCI; University of Michigan; Gateway for Cancer Research | Advisory Board (Takeda; Agenesis; Pfizer; Glaxo-Smith Kline; Kyowa Kirin Pharmaceutical Development; Kineta; I-Mab; Mekanistic; Acuate Therapeutics; Atreca Development; Schrodinger; Prelude; Wells Therapeutics; Kivu; Compass Tx; Zai Lab; Abdera; AstraZeneca; EMD Serono) Clinical Advisory Board (Quanta Therapeutics) Scientific Advisory Board (Cullinan) STING Agonist Global Advisory Board (Boehringer Ingelheim) Consultant (SOTIO; I-Mab) Data Monitoring Committee (Amgen CodeBreak 202) Data Safety Monitoring Board (DrenBio) Research Funding (National Cancer Institute/NIH/DDHS; AstraZeneca |

FACULTY DISCLOSURE INFORMATION

| | | | | |
|----------------------------|-------------------------------|----------|---|---|
| | | | | Pharmaceutical LP; Merck; Genentech Inc.; NIH/NCI; University of Michigan; Gateway for Cancer Research/ASCO) |
| Maues, Julia | Speaker | X | | |
| Moore, Kathleen, MD | Moderator/ Speaker | | Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE | Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) Travel, Accommodations, Expenses (BioNTech SE) |
| Naqash, Abdul Rafeh, MD | Speaker | | Foundation Med; JCO Precision Oncology; Jazz Pharma; Loxo@Lilly; Surface Oncology; ADC Therapeutics; IGM Biosciences; EMD Serono; Aravive; Nikang Therapeutics; Inspirna; Exelixis; Revolution Medicine; Jacobio; Pionyr; Jazz Pharmaceuticals; NGM Biopharmaceuticals; Immunocore, Phanes Therapeutics; Kymera Therapeutics | Honoraria (Foundation Med) Consultant (JCO Precision Oncology) Travel (Jazz Pharma) Research Funding to Institution (Loxo@Lilly; Surface Oncology; ADC Therapeutics; IGM Biosciences; EMD Serono; Aravive; Nikang Therapeutics; Inspirna; Exelixis; Revolution Medicine; Jacobio; Pionyr; Jazz Pharmaceuticals; NGM Biopharmaceuticals; Immunocore, Phanes Therapeutics; Kymera Therapeutics) |
| Price, Lauren, PharmD | Speaker | X | | |
| Ricciuti, Biagio, MD | Speaker | | AstraZeneca; Regeneron; AbbVie; Bayer; BMS; Caris Life; SITC | Consultant (AstraZeneca; Regeneron; AbbVie; Bayer; BMS; Caris Life) Speaker Fee (AstraZeneca) Honorarium (SITC) |
| Tarantino, Paolo, MD | Moderator/ Speaker | | AstraZeneca, Daiichi Sankyo, Novartis, Menarini/Stemline, Gilead, Eli Lilly | Consultant (AstraZeneca; Daiichi Sankyo; Gilead; Eli Lilly) Advisor (AstraZeneca; Daiichi Sankyo; Novartis; Menarini/Stemline) Speaker (AstraZeneca; Daiichi Sankyo) |
| Holley Engbert | Staff | X | | |
| Heather Rush | Staff | X | | |
| Kara Shumaker | Reviewer/Staff | X | | |
| Michelle N Small, MPH | Reviewer/Staff | X | | |
| Angeles Alvarez Secord, MD | Reviewer/Edu-Chair | | AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ; | Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses |

FACULTY DISCLOSURE INFORMATION

| | | | | |
|---------------------|------------------------------|----------|--|---|
| | | | GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Bio | Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio) |
| Linda Duska, MD | Reviewer/Edu-Co-Chair | | Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp | Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp |
| Stephanie Blank, MD | Reviewer | | AstraZeneca; Merck; Zentalis; Acrivon; Seattle Genetics; GSK | Research Funding to Institution |
| David Mutch, MD | Reviewer | X | | |
| Susan Zweizig, MD | Reviewer | X | | |